Timeline: Insulin Market Under Scrutiny

The price of lifesaving diabetes drugs has skyrocketed over the past decade. And patients aren’t the only ones who have noticed. Five states and a federal prosecutor are demanding information from insulin manufacturers and the pharmaceutical industry’s financial middlemen.

Below, we detail when legal action related to insulin drugs began, with links to documents.

March 2016

The U.S. Attorney’s Office for the Southern District of New York launches the first of several civil investigative demands (CIDs), beginning with Sanofi and Novo Nordisk.

The note, like those of Eli Lilly and Sanofi, establishes that the federal prosecutor is interested in the company's business relationships with pharmacy benefit managers and demands information on specific insulins.

July 2016


August 2016


November 2016


January 2017

Minnesota's State Attorney General's office appears as the first state to issue a civil investigative demand in federal filings.

February 2017


March 2017

Attorneys allege that the relationship between drug manufacturers and pharmacy benefit managers harms patients and allows for rising insulin prices.

April 2017


May 2017


July 2017


September 2017


KHN’s coverage of these topics is supported by
John A. Hartford Foundation
and
Laura and John Arnold Foundation